APLS · As filed with the SEC
Apellis Pharmaceuticals cash flow statement, by quarter
The statement as Apellis Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Statements of Cash Flows (Unaudited) · USD
| USD | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net income/(loss) | 18,656,000 | — | — | — |
| Adjustments to reconcile net income/(loss) to net cash used in operating activities: | ||||
| Share-based compensation expense | 25,173,000 | — | — | — |
| Depreciation expense | 291,000 | — | — | — |
| Amortization of discounts for credit facility | 579,000 | — | — | — |
| Amortization of discounts for convertible notes | 82,000 | — | — | — |
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | (74,068,000) | — | — | — |
| Inventory | 18,806,000 | — | — | — |
| Prepaid and other current assets | (11,270,000) | — | — | — |
| Other assets | (292,000) | — | — | — |
| Right-of-use assets and lease liabilities | (16,000) | — | — | — |
| Accounts payable | (7,741,000) | — | — | — |
| Accrued expenses and other liabilities | (31,166,000) | — | — | — |
| Net cash used in operating activities | (60,966,000) | — | — | — |
| Financing Activities | ||||
| Proceeds from exercise of stock options | 86,000 | — | — | — |
| Payments of employee tax withholding related to equity-based compensation | (22,000) | — | — | — |
| Net cash provided by financing activities | 64,000 | — | — | — |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (131,000) | — | — | — |
| Net decrease in cash, cash equivalents and restricted cash | (61,033,000) | — | — | — |
| Cash, cash equivalents and restricted cash at beginning of period | 467,760,000 | 480,601,000 | 371,466,000 | 359,827,000 |
| Cash, cash equivalents and restricted cash at end of period | 406,727,000 | 467,760,000 | 480,601,000 | 371,466,000 |
| Supplemental Disclosures | ||||
| Cash paid for interest | 10,476,000 | — | — | — |
| Cash paid for income taxes | 66,000 | — | — | — |
| Lease assets obtained in exchange for operating lease liabilities | 2,400,000 | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.